Sponsors (6)
Official title: Apply user fees with respect to tobacco products deemed subject to the requirements of chapter IX of the Federal Food, Drug, and Cosmetic Act.
Introduced March 26, 2026 by Jeanne Shaheen · Last progress March 26, 2026
The bill strengthens and stabilizes FDA tobacco‑regulatory funding and transparency (including youth e‑cigarette education) by broadening and indexing user fees, but does so at the cost of higher compliance burdens and fees for manufacturers (especially small businesses), potential price impacts for consumers, increased agency reporting work, and risks to sensitive business data.
All Americans (via FDA) gain a larger, inflation‑adjusted user‑fee pool to fund tobacco product review and regulatory activities beginning FY2027, strengthening FDA capacity for oversight and public‑health review.
Manufacturers and importers (and the fee system) will begin applying fees across all tobacco product classes starting FY2029 — including classes added later by rule — broadening the revenue base and spreading costs more equitably among producers.
Parents, children, and taxpayers benefit from increased transparency because FDA must report how much is spent on youth e‑cigarette education and disclose the spending split between deemed (e.g., e‑cigarettes) and combustible tobacco activities.
Manufacturers and importers — especially small businesses — will face new reporting requirements and likely higher fee bills, increasing their compliance costs and financial burden.
Consumers and taxpayers may face higher prices over time because indexing the user‑fee pool to CPI‑U will likely increase total fees collected, which firms may pass through to consumers.
Manufacturers and small businesses risk exposure of proprietary or sensitive sales and financial data because the bill requires detailed sales reporting and financial breakdowns unless robust protections/redactions are applied.
Based on analysis of 3 sections of legislative text.
Raises and CPI‑indexes the FDA tobacco user‑fee pool, expands fees to all tobacco product classes by FY2029, and requires new fee‑and‑spending report breakdowns focused on youth vaping prevention.
The bill raises and indexes the FDA’s annual tobacco product user-fee pool, extends user fees to all classes of tobacco products beginning in fiscal year 2029, and requires the FDA to allocate fees for newly deemed product classes using a sales-based formula. It also expands annual reporting requirements to show spending and fee collection breakdowns for ENDS (e‑cigarette) prevention education and for newly deemed tobacco-product classes, with some report items phased in for FY2027 and FY2029. Overall, the law increases predictable funding for FDA tobacco regulation and youth vaping prevention, broadens which product classes pay user fees, ties future fee totals to inflation (CPI‑U), and adds transparency requirements about how fee revenue is spent and allocated across product classes and public education efforts aimed at youth.